Neurotensin receptors in adeno- and squamous cell carcinoma

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3527-3533

  Haase, Cathleen ^a   Bergmann, R ^a   Oswald, J ^a   Zips, D ^b   Pietzsch, J ^a  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

FaDu; HT 29; Neurotensin; Neurotensin receptor; Tumor xenograft model

Indexed keywords

BUTYRIC ACID; MESSENGER RNA; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; NEUROTENSIN RECEPTOR 2; NEUROTENSIN RECEPTOR 3; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BUTYRATES; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; COLONIC NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; MICE; MICE, NUDE; RECEPTORS, NEUROTENSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 33750706887     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24: 389-427, 2003.
2. Reubi JC, Macke HR and Krenning EP: Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46: 67-75, 2005.
3. Kitabgi P: Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes. Curr Opin Drug Discov Devel 5: 764-776, 2002.
4. Davis TP, Burgess HS, Crowell S, Moody TW, Culling-Berglund A and Liu RH: Beta-endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells. Eur J Pharmacol 161: 283-285, 1989.
5. Ishizuka J, Townsend CM Jr and Thompson JC: Neurotensin regulates growth of human pancreatic cancer. Ann Surg 217: 439-446, 1993.
6. Bozou JC, Amar S, Vincent JP and Kitabgi P: Neurotensin-mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase. Mol Pharmacol 29: 489-496, 1986.
7. Vincent JP, Mazella J and Kitabgi P: Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20: 302-309, 1999.
8. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen C, Kliemannel M, Schwarz E, Willnow TE, Hempstead BL and Petersen CM: Sortilin is essential for proNGF-induced neuronal cell death. Nature 427: 843-848, 2004.
9. Carraway R and Leeman SE: The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248: 6854-6861, 1973.
10. Kitabgi P, Carraway R and Leeman SE: Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J Biol Chem 251: 7053-7058, 1976.
11. Evers BM, Izukura M, Chung DH, Parekh D, Yoshinaga K, Greeley GH Jr, Uchida T, Townsend CM Jr and Thompson JC: Neurotensin stimulates growth of colonic mucosa in young and aged rats. Gastroenterology 103: 86-91, 1992.
12. Navarro V, Martin S, Sarret P, Nielsen MS, Petersen CM, Vincent J and Mazella J: Pharmacological properties of the mouse neurotensin receptor 3. Maintenance of cell surface receptor during internalization of neurotensin. FEBS Lett 495: 100-105, 2001.
13. Dal Farra C, Sarret P, Navarro V, Botto JM, Mazella J and Vincent JP: Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int J Cancer 92: 503-509, 2001.
14. Maoret JJ, Pospai D, Rouyer-Fessard C, Couvineau A, Laboisse C, Voisin T and Laburthe M: Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun 205: 465-471, 1994.
15. Reubi JC, Waser B, Friess H, Buchler M and Laissue J: Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 42: 546-550, 1998.
16. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M and Maihle NJ: Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA 91: 4673-4677, 1994.
17. Ocejo-Garcia M, Ahmed SI, Coulson JM and Woll PJ: Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. Lung Cancer 33: 1-9, 2001.
18. Yaromina A, Holscher T, Eicheler W, Rosner A, Krause M, Hessel F, Petersen C, Thames HD, Baumann M and Zips D: Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma? Radiother Oncol 76: 206-212, 2005.
19. Petersen C, Zips D, Krause M, Volkel W, Thames HD and Baumann M: Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. Radiother Oncol 74: 331-336, 2005.
20. Baumann M, Krause M, Zips D, Eicheler W, Dorfler A, Ahrens J, Petersen C, Bruchner K and Hilberg F: Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse. Int J Radiat Biol 79: 547-559, 2003.
21. Lehner I, Niehof M and Borlak J: An optimized method for the isolation and identification of membrane proteins. Electrophoresis 24: 1795-1808, 2003.
22. Yamada M, Ohata H, Momose K and Richelson E: Pharmacological characterization of SR 48692 sensitive neurotensin receptor in human pancreatic cancer cells, MIA PaCa-2. Res Commun Mol Pathol Pharmacol 90: 37-47, 1995.
23. Wang L, Friess H, Zhu Z, Graber H, Zimmermann A, Korc M, Reubi JC and Buchler MW: Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin Cancer Res 6: 566-571, 2000.
24. Chabry J, Labbe-Jullie C, Gully D, Kitabgi P, Vincent JP and Mazella J: Stable expression of the cloned rat brain neurotensin receptor into fibroblasts: binding properties, photoaffinity labeling, transduction mechanisms, and internalization. J Neurochem 63: 19-27, 1994.
25. Yamada M, Lombet A, Forgez P and Rostene W: Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Life Sci 62: 375-380, 1998.
26. Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr 133: 2485-2493, 2003.
27. Pellizzaro C, Coradini D and Daidone MG: Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29. Carcinogenesis 23: 735-740, 2002.
28. Coradini D, Pellizzaro C, Marimpietri D, Abolafio G and Daidone MG: Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. Cell Prolif 33: 139-146, 2000.
29. Orchel A, Dzierzewicz Z, Parfiniewicz B, Weglarz L and Wilczok T: Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent. Dig Dis Sci 50: 490-498, 2005.
30. Stokrova J, Sovova V, Sloncova E, Kucerova D, Tuhackova, Z and Korb J: Response of HT115, a highly invasive human colorectal adenocarcinoma cell line, to sodium butyrate treatment and glucose deprivation. Int J Oncol 26: 793-799, 2005.
31. McBain JA, Weese JL, Meisner LF, Wolberg WH and Willson JK: Establishment and characterization of human colorectal cancer cell lines. Cancer Res 44: 5813-5821, 1984.
32. Navarro V, Vincent JP and Mazella J: Shedding of the luminal domain of the neurotensin receptor-3/sortilin in the HT29 cell line. Biochem Biophys Res Commun 298: 760-764, 2002.
33. Martin S, Navarro V, Vincent JP and Mazella J: Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line. Gastroenterology 123: 1135-1143, 2002.
34. Morinville A, Martin S, Lavallee M, Vincent JP, Beaudet A and Mazella J: Internalization and trafficking of neurotensin via NTS3 receptors in HT29 cells. Int J Biochem Cell Biol 36: 2153-2168, 2004.